Milestone Pharmaceuticals (NASDAQ:MIST – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for […]
Milestone Pharmaceuticals (NASDAQ:MIST – Get Rating) issued its earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04), MarketWatch Earnings reports. Shares of NASDAQ:MIST opened at $6.54 on Friday. Milestone Pharmaceuticals has a 1 year low of $3.98 and a 1 year high […]
Millennium Management LLC trimmed its position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Get Rating) by 3.3% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 695,241 shares of the company’s stock after selling 23,389 shares during the period. Millennium Management LLC owned about 2.33% of Milestone Pharmaceuticals […]